This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Koivisto, P. A. Articles by Trapman, J. Search for Related Content PubMed PubMed Citation Articles by Koivisto, P. A. Articles by Trapman, J.

Androgen Receptor Gene Alterations and Chromosomal Gains and Losses in Prostate Carcinomas Appearing During Finasteride Treatment for Benign Prostatic Hyperplasia¹

Laboratory of Cancer Genetics [P. A. K., J. S., O-P K.], Department of Clinical Chemistry, and Department of Pathology [H. H.], Tampere University Hospital, FIN-33521 Tampere, Finland; Laboratory of Cancer Genetics, National Center for Human Genome Research, NIH, Bethesda, Maryland 20892 [O-P. K.]; and Department of Pathology, Erasmus University, 3000 DR Rotterdam, the Netherlands [C. E-v. E, J. T.]

Finasteride is commonly used for the treatment of benign prostatic hyperplasia and has been suggested to prevent prostate cancer development. To gain insight to the molecular effects of finasteride on prostate cancer development, we studied six prostate cancers diagnosed during finasteride treatment for benign prostatic hyperplasia. Comparative genomic hybridization detected genetic alterations in four tumors (1–5 changes/tumor). Xq gains and 6q losses were the most common alterations. The recurrent Xq gains motivated us to study the involvement of the androgen receptor (AR) gene. One tumor with Xq gain had a 3-fold amplification of the AR gene, suggesting that tumor development in finasteride-treated patients may require increased AR copy number and expression, as has previously been shown for prostate cancers recurring during hormonal therapy. Furthermore, in another tumor, an Arg726Leu mutation of the AR gene was found. This mutation was also present in the germ-line DNA of the patient. Arg726Leu mutation has previously been reported to affect the transactivational properties of the AR. In summary, prostate cancers developing during finasteride therapy may have distinct biological properties, such as a low number of chromosomal alterations and frequent involvement of the AR gene. Further studies are needed to explore the role of germ-line AR mutations in these patients.

This article has been cited by other articles:

				J. Li and J. Kim Molecular Profiles of Finasteride Effects on Prostate Carcinogenesis Cancer Prevention Research, June 1, 2009; 2(6): 518 - 524. [Abstract] [Full Text] [PDF]

				M. S. Lucia, J. I. Epstein, P. J. Goodman, A. K. Darke, V. E. Reuter, F. Civantos, C. M. Tangen, H. L. Parnes, S. M. Lippman, F. G. La Rosa, et al. Finasteride and High-Grade Prostate Cancer in the Prostate Cancer Prevention Trial J Natl Cancer Inst, September 19, 2007; 99(18): 1375 - 1383. [Abstract] [Full Text] [PDF]

				M. E. Grossmann, H. Huang, and D. J. Tindall Androgen Receptor Signaling in Androgen-Refractory Prostate Cancer J Natl Cancer Inst, November 21, 2001; 93(22): 1687 - 1697. [Abstract] [Full Text] [PDF]

				N. Mononen, K. Syrjäkoski, M. Matikainen, T. L. J. Tammela, J. Schleutker, O.-P. Kallioniemi, J. Trapman, and P. A. Koivisto Two Percent of Finnish Prostate Cancer Patients Have a Germ-line Mutation in the Hormone-binding Domain of the Androgen Receptor Gene Cancer Res., November 1, 2000; 60(22): 6479 - 6481. [Abstract] [Full Text]